Clinical trial
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to…
NCT00040755 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00040755 |
|---|---|
| Title | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | rebimastat, laboratory biomarker analysis |
| Enrollment | 68 |
| Start date | May 1, 2002 |
| Primary completion | Jul 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: